Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Show More...
-
Website https://www.adverum.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 2.22 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -0.09 -0.25 -2.46 -1.86 -3.14 -1.29 -1.18 -1.01 -1.01 Dividends USD Payout Ratio % * Shares Mil 21.0 21.0 12.0 25.0 36.0 44.0 61.0 64.0 64.0 Book Value Per Share * USD 6.84 10.14 5.65 3.69 3.42 2.44 2.19 Free Cash Flow Per Share * USD -0.08 -1.33 -1.27 -1.01 -0.95 -0.91 Return on Assets % -469.17 -717.34 -35.14 -22.27 -45.6 -25.73 -34.97 -29.57 -29.57 Financial Leverage (Average) 1.08 1.05 1.09 1.1 1.06 1.27 1.27 Return on Equity % -40.54 -23.6 -48.59 -28.1 -37.71 -34.29 -34.29 Return on Invested Capital % -40.51 -23.6 -48.59 -28.1 -37.71 -29.27 -29.27 Interest Coverage -225.38 -71.27 Current Ratio 0.46 0.71 29.3 39.7 22.76 18.15 19.48 9.06 9.06 Quick Ratio 0.43 0.49 29.14 39.48 22.54 17.85 19.13 8.55 8.55 Debt/Equity 0.16 0.16